天天舔天天爽_视频日韩_成人网线_天天草草草_免费一级在线观看_色综合色综合色综合色综合

英國(guó)Enigma Diagnostics  
Enigma DiagnosticsLimited是一家總部位于英國(guó)的未上市公司，致力于為分散和即時(shí)設(shè)置開(kāi)發(fā)新一代快速分子診斷儀器平臺(tái)。

　　Enigma的創(chuàng)新型專有技術(shù)將實(shí)時(shí)聚合酶鏈反應(yīng)的速度和靈敏度與現(xiàn)場(chǎng)分散與即時(shí)測(cè)試所需的簡(jiǎn)易性相結(jié)合，可以在45分鐘之內(nèi)提供原始樣本的測(cè)試結(jié)果。

　　該公司正瞄準(zhǔn)眾多價(jià)值數(shù)十億英磅的市場(chǎng)，重點(diǎn)則放在臨床和高值應(yīng)用市場(chǎng)。Enigma的商業(yè)戰(zhàn)略是最大化其市場(chǎng)領(lǐng)先的快速診斷即時(shí)與現(xiàn)場(chǎng)設(shè)備與化驗(yàn)平臺(tái)的持續(xù)運(yùn)轉(zhuǎn)帶來(lái)的營(yíng)收，這些設(shè)備和平臺(tái)來(lái)源于該公司廣泛的已發(fā)布和提交專利申請(qǐng)的知識(shí)產(chǎn)權(quán)組合。Enigma將與一些市場(chǎng)領(lǐng)導(dǎo)者合作，這些市場(chǎng)領(lǐng)導(dǎo)者需要有全球的市場(chǎng)滲透力，并且要適當(dāng)建立內(nèi)部銷售和營(yíng)銷能力以指導(dǎo)其產(chǎn)品的分銷過(guò)程。

　　Enigma 擁有 Defence Science TechnologyLaboratory授予的一系列專利（這些專利體現(xiàn)了英國(guó)國(guó)防部 (UK Ministry ofDefence)逾15年來(lái)對(duì)研究的大力支持）的獨(dú)家許可以及美國(guó)應(yīng)用生物系統(tǒng)公司 (Applied Biosystems) 和CeleraLicences的實(shí)時(shí)聚合酶鏈反應(yīng)設(shè)備推廣的許可。Enigma的研發(fā)活動(dòng)已經(jīng)產(chǎn)生了50多個(gè)致力于實(shí)時(shí)聚合酶鏈反應(yīng)和更廣泛分子技術(shù)的全球?qū)＠盗小＿@些專利中有許多已經(jīng)得到美國(guó)、歐盟和日本等核心商業(yè)地區(qū)的承認(rèn)，并且在眾多其它關(guān)鍵地區(qū)也有范圍更廣的申請(qǐng)和授權(quán)。

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings. Enigma’s innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma’s commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of- care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.